Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00— vs Q3 2019 Net Income-$7.37M-$7.37MN/M vs Q3 2019 EPS Diluted-$0.16-$0.16N/M vs Q3 2019 Operating Income-$7,376,167N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
derived
ended Sep 30, 2020 · filed Nov 9, 2020 · 40 d after period end